RxDoctor Payments Data

Jeffrey Floyd, MD

Family Medicine · Oklahoma City, OKNPI 1629002761

Payments from drug & device makers

$8,964in general payments, 2019–2025

Across 562 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$980
  • Novo Nordisk$725
  • AstraZeneca$639
  • Amgen$621
  • Teva Pharmaceuticals USA, Inc.$497
  • Pfizer$407
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,73397%
  • Education$1111%
  • Gifts$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)61$980
Novo Nordisk72$725
AstraZeneca30$639
Amgen40$621
Teva Pharmaceuticals USA, Inc.21$497
Pfizer28$407
Lilly USA, LLC26$396
GSK35$385
Boehringer Ingelheim17$295
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$282
Takeda Pharmaceuticals U.S.A., Inc.13$282
IBSA Pharma Inc.9$249
Mannkind Corporation9$233
Amarin Pharma, Inc.16$212
Bayer12$195
Supernus Pharmaceuticals, Inc.9$189
Abbott11$176
Ironshore Pharmaceuticals Inc.8$144
Actelion Pharmaceuticals US, Inc.7$137
Eisai Inc.8$127
Corium, LLC7$121
Johnson & Johnson(2 entities)8$120
Astellas Pharma US Inc7$118
Sanofi-aventis U.S. LLC6$91
Merck6$84
Harmony Biosciences LLC4$79
Shire North American Group Inc5$76
Corcept Therapeutics4$74
Axsome Therapeutics, Inc.4$65
Biohaven Pharmaceutical Holding Company Ltd.4$64
Biohaven Pharmaceuticals, Inc.4$62
Dynavax Technologies Corporation4$60
Inspire Medical Systems, Inc.3$54
Noven Therapeutics, LLC4$54
Gilead2$53
Boston Scientific2$52
Nabriva Therapeutics, PLC3$50
Antares Pharma, Inc.3$49
Nevro Corp.2$39
Novartis2$31
Tandem Diabetes Care, Inc.1$30
Therapeuticsmd, Inc.2$27
Almatica Pharma LLC2$27
Halozyme Inc2$26
Sumitomo Pharma America, Inc.1$25
Phathom Pharmaceuticals, Inc.3$25
Fresenius Kabi USA, LLC1$19
Otsuka America Pharmaceutical, Inc.1$19
Edwards Lifesciences1$18
Nalu Medical, Inc.1$17
Ultragenyx Pharmaceutical Inc.1$17
Cequr Corporation1$17
Tonix Medicines, Inc.1$16
Vertical Pharmaceuticals, LLC1$16
Collegium Pharmaceutical, Inc.1$15
Azurity Pharmaceuticals, Inc.1$15
Genentech USA, Inc.1$15
Lundbeck LLC1$15
Arbor Pharmaceuticals, Inc.1$14
Paratek Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,964 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$153,470
Medicare patients
610
Services billed
2,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$153,570
JardianceEmpagliflozin75$97,137
EliquisApixaban83$89,546
TrulicityDulaglutide38$60,660
ForteoTeriparatide12$59,921
Nurtec OdtRimegepant Sulfate28$51,460
MounjaroTirzepatide41$47,046
JanuviaSitagliptin Phosphate31$32,002
MyrbetriqMirabegron30$28,484
RybelsusSemaglutide19$26,377
AfrezzaInsulin Regular, Human21$22,267
XareltoRivaroxaban17$16,556
TradjentaLinagliptin16$16,104
Celecoxib183$9,502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen271$8,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$725$179,948146 claims
Lilly USA, LLCTrulicity, Forteo, Mounjaro$396$167,62791 claims
PfizerEliquis, Nurtec Odt, Premarin$407$149,074130 claims
Boehringer IngelheimJardiance, Tradjenta$295$113,24191 claims
MerckJanuvia$84$32,00231 claims
Astellas Pharma US IncMyrbetriq$118$28,48430 claims
Mannkind CorporationAfrezza$233$22,26721 claims
Johnson & JohnsonXarelto$120$16,55617 claims
GSKBreo Ellipta$385$5,06912 claims
AbbVieSynthroid$980$3,45752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →